Southwest Securities released a research report on April 23 stating that it gave Baig Biotech (688276.SH) a purchase rating. The main reasons for the rating include: 1) continuous dosage of the shingles vaccine; 2) quarterly fluctuations in shingles vaccine delivery, which can be expected throughout the year; 3) investing in mRNA technology platforms to effectively promote the development and layout of various mRNA vaccines and promote the company's diversification of technology and products. (Mainichi Keizai Shimbun)
西南证券4月23日发布研报称，给予百克生物（688276.SH）买入评级。评级理由主要包括：1）带状疱疹疫苗持续放量；2）带状疱疹疫苗发货季度间波动，全年放量可期；3）投资mRNA技术平台，有效推进多种mRNA疫苗的研发和布局，促进公司实现技术及产品多元化。（每日经济新闻）
Southwest Securities released a research report on April 23 stating that it gave Baig Biotech (688276.SH) a purchase rating. The main reasons for the rating include: 1) continuous dosage of the shingles vaccine; 2) quarterly fluctuations in shingles vacci
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.